Protocol of a population-based prospective COVID-19 cohort study Munich, Germany (KoCo19).

Autor: Radon K; Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Ludwig-Maximilians-Universität (LMU) University Hospital Munich, Ziemssenstr. 1, 80336, Munich, Germany. katja.radon@med.lmu.de.; Center for International Health, LMU University Hospital, Munich, Germany. katja.radon@med.lmu.de., Saathoff E; Division of Infectious Diseases and Tropical Medicine, LMU University Hospital Munich, Germany, Leopoldstrasse 5, 80802, Munich, Germany.; German Center for Infection Research (DZIF), partner site Munich, Munich, Germany., Pritsch M; Division of Infectious Diseases and Tropical Medicine, LMU University Hospital Munich, Germany, Leopoldstrasse 5, 80802, Munich, Germany., Guggenbühl Noller JM; Division of Infectious Diseases and Tropical Medicine, LMU University Hospital Munich, Germany, Leopoldstrasse 5, 80802, Munich, Germany., Kroidl I; Division of Infectious Diseases and Tropical Medicine, LMU University Hospital Munich, Germany, Leopoldstrasse 5, 80802, Munich, Germany.; German Center for Infection Research (DZIF), partner site Munich, Munich, Germany., Olbrich L; Division of Infectious Diseases and Tropical Medicine, LMU University Hospital Munich, Germany, Leopoldstrasse 5, 80802, Munich, Germany., Thiel V; Division of Infectious Diseases and Tropical Medicine, LMU University Hospital Munich, Germany, Leopoldstrasse 5, 80802, Munich, Germany., Diefenbach M; Division of Infectious Diseases and Tropical Medicine, LMU University Hospital Munich, Germany, Leopoldstrasse 5, 80802, Munich, Germany., Riess F; Division of Infectious Diseases and Tropical Medicine, LMU University Hospital Munich, Germany, Leopoldstrasse 5, 80802, Munich, Germany., Forster F; Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Ludwig-Maximilians-Universität (LMU) University Hospital Munich, Ziemssenstr. 1, 80336, Munich, Germany., Theis F; Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764, Neuherberg, Germany.; Departments of Mathematics and Life Sciences, Technical University of Munich, Munich, Germany., Wieser A; Division of Infectious Diseases and Tropical Medicine, LMU University Hospital Munich, Germany, Leopoldstrasse 5, 80802, Munich, Germany.; Max von Pettenkofer Institute, Faculty of Medicine, LMU of Munich, Munich, Germany., Hoelscher M; Center for International Health, LMU University Hospital, Munich, Germany.; Division of Infectious Diseases and Tropical Medicine, LMU University Hospital Munich, Germany, Leopoldstrasse 5, 80802, Munich, Germany.; German Center for Infection Research (DZIF), partner site Munich, Munich, Germany.
Jazyk: angličtina
Zdroj: BMC public health [BMC Public Health] 2020 Jun 30; Vol. 20 (1), pp. 1036. Date of Electronic Publication: 2020 Jun 30.
DOI: 10.1186/s12889-020-09164-9
Abstrakt: Background: Due to the SARS-CoV-2 pandemic, public health interventions have been introduced globally in order to prevent the spread of the virus and avoid the overload of health care systems, especially for the most severely affected patients. Scientific studies to date have focused primarily on describing the clinical course of patients, identifying treatment options and developing vaccines. In Germany, as in many other regions, current tests for SARS-CoV2 are not conducted on a representative basis and in a longitudinal design. Furthermore, knowledge about the immune status of the population is lacking. Nonetheless, these data are needed to understand the dynamics of the pandemic and hence to appropriately design and evaluate interventions. For this purpose, we recently started a prospective population-based cohort in Munich, Germany, with the aim to develop a better understanding of the state and dynamics of the pandemic.
Methods: In 100 out of 755 randomly selected constituencies, 3000 Munich households are identified via random route and offered enrollment into the study. All household members are asked to complete a baseline questionnaire and subjects ≥14 years of age are asked to provide a venous blood sample of ≤3 ml for the determination of SARS-CoV-2 IgG/IgA status. The residual plasma and the blood pellet are preserved for later genetic and molecular biological investigations. For twelve months, each household member is asked to keep a diary of daily symptoms, whereabouts and contacts via WebApp. If symptoms suggestive for COVID-19 are reported, family members, including children < 14 years, are offered a pharyngeal swab taken at the Division of Infectious Diseases and Tropical Medicine, LMU University Hospital Munich, for molecular testing for SARS-CoV-2. In case of severe symptoms, participants will be transferred to a Munich hospital. For one year, the study teams re-visits the households for blood sampling every six weeks.
Discussion: With the planned study we will establish a reliable epidemiological tool to improve the understanding of the spread of SARS-CoV-2 and to better assess the effectiveness of public health measures as well as their socio-economic effects. This will support policy makers in managing the epidemic based on scientific evidence.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje